Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Abstract #CR04

Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts, Breast Cancer

Presenter: Jodi Taraba, PharmD, MS, BCOP, Breast Clinical Pharmacist, Mayo Clinic, Rochester, MN

Co-Authors: Allison Golbach, PharmD, The University of Kansas Health System, Kansas City, KS; Matt Smith, PharmD, Mayo Clinic, Rochester, MN; Kristin Mara, MS, Mayo Clinic, Rochester, MN; Karthik Giridhar, MD, Mayo Clinic, Rochester, MN

BACKGROUND: The use of cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor (HER)2-negative breast cancer is rising.1-5 Managing oral oncology agents remotely, using a patient-centered model, was challenging in our previous practice. Our group developed a pharmacist-led, multidisciplinary virtual clinic to improve the management of patients who are receiving CDK4/6 inhibitors.

OBJECTIVES: To evaluate the adherence to recommended laboratory monitoring in patients using palbociclib therapy; to identify areas for optimization, including the development of a pharmacist-led CDK4/6 inhibitor virtual clinic; and to assess the impact of this clinic on adverse events, adherence, laboratory monitoring, and the identification of drug–drug interactions.

METHOD: This study included 2 cohorts, a retrospective cohort and a prospective cohort. The retrospective cohort included patients with HR-positive, HER2-negative breast cancer who initiated palbociclib therapy between May 8, 2018, and June 4, 2019; were aged ≥18 years; and had a diagnosis of advanced or metastatic breast cancer. The prospective cohort included patients receiving a CDK4/6 inhibitor—palbociclib, abemaciclib, or ribociclib—who were enrolled in the virtual clinic between May 1, 2020, and April 10, 2021. For both cohorts, the data were collected for up to the first 6 cycles of therapy. The primary outcome was the rate of adherence to recommended CDK4/6 inhibitor therapy, by laboratory monitoring, defined as laboratory blood draws every 2 weeks for the first 2 cycles and before the start of each cycle thereafter ± 3 days. The secondary outcomes included the rate of medication adherence, as reported by the patient, and assessment of potential drug interactions.

RESULTS: Patients managed by the virtual clinic were contacted, primarily via phone, every 2 weeks for the first 2 months, then monthly thereafter. These virtual visits included review of laboratory test results, medication adherence, adverse events assessment, medication reconciliation, and screening for drug interactions. Laboratory tests were appropriately done at 462 of 541 time points in the 81 patients in the retrospective cohort, and at 128 of 139 time points in the 28 patients in the prospective cohort (85.4% vs 92.1%; P = .038). The patient-reported adherence to the prescribed medication was more than 99%. A total of 38 potential drug therapy problems were identified. The interventions included patient education during therapy administration, thereby increasing adherence, symptom management, drug–supplement interactions, and monitoring of QT interval prolongation.

CONCLUSION: The implementation of a pharmacist-led virtual clinic significantly improved adherence to laboratory testing in patients receiving CDK4/6 inhibitor therapy and is now a sustained model in our clinical practice. The development and implementation of interactive care plans to use technology for the management of patients receiving CDK4/6 inhibitors is ongoing.

  1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936.
  2. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926-1936.
  3. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738-1748. Erratum in: N Engl J Med. 2018;379:2582.
  4. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465-2472.
  5. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638-3646.
Related Items
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.